Intrahepatic islet transplantation in patients with type 1 diabetes is limited by donor availability and lack of engraftment. Alternative β cell sources and transplantation sites are needed. We demonstrate the feasibility to repurpose a decellularized lung as an endocrine pancreas for β cell replacement. We bioengineer an induced pluripotent stem cell (iPSC)-based version, fabricating a human iPSC-based vascularized endocrine pancreas (iVEP) using iPSC-derived β cells (iPSC-derived islets [SC-islets]) and endothelial cells (iECs). SC-islets and iECs are aggregated into vascularized iβ spheroids (ViβeSs), and over 7 days of culture, spheroids integrate into the bioengineered vasculature, generating a functional, perfusable human endocrine organ. In vitro, the vascularized extracellular matrix (ECM) sustained SC-islet engraftment and survival with a significantly preserved β cell mass and a physiologic insulin release. In vivo, iVEP restores normoglycemia in diabetic NSG mice. We report a human iVEP providing a controlled in vitro insulin-secreting phenotype and in vivo function.

Bioengineering of a human iPSC-derived vascularized endocrine pancreas for type 1 diabetes / Campo, F.; Neroni, A.; Pignatelli, C.; Pellegrini, S.; Marzinotto, I.; Valla, L.; Manenti, F.; Policardi, M.; Lampasona, V.; Piemonti, L.; Citro, A.. - In: CELL REPORTS MEDICINE. - ISSN 2666-3791. - 6:2(2025). [10.1016/j.xcrm.2025.101938]

Bioengineering of a human iPSC-derived vascularized endocrine pancreas for type 1 diabetes

Campo F.
Primo
;
Neroni A.
Secondo
;
Marzinotto I.;Piemonti L.
Penultimo
;
2025-01-01

Abstract

Intrahepatic islet transplantation in patients with type 1 diabetes is limited by donor availability and lack of engraftment. Alternative β cell sources and transplantation sites are needed. We demonstrate the feasibility to repurpose a decellularized lung as an endocrine pancreas for β cell replacement. We bioengineer an induced pluripotent stem cell (iPSC)-based version, fabricating a human iPSC-based vascularized endocrine pancreas (iVEP) using iPSC-derived β cells (iPSC-derived islets [SC-islets]) and endothelial cells (iECs). SC-islets and iECs are aggregated into vascularized iβ spheroids (ViβeSs), and over 7 days of culture, spheroids integrate into the bioengineered vasculature, generating a functional, perfusable human endocrine organ. In vitro, the vascularized extracellular matrix (ECM) sustained SC-islet engraftment and survival with a significantly preserved β cell mass and a physiologic insulin release. In vivo, iVEP restores normoglycemia in diabetic NSG mice. We report a human iVEP providing a controlled in vitro insulin-secreting phenotype and in vivo function.
2025
beta cell replacement; extracellular matrix; human iPSC vascularized endocrine spheroids; induced pluripotent stem cells; iPSCs; islet transplantation; lung scaffold; organ decellularization; organ engineering for type 1 diabetes; pancreas bioengineering; tissue engineering; type 1 diabetes
File in questo prodotto:
File Dimensione Formato  
main.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 6.13 MB
Formato Adobe PDF
6.13 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/180756
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact